#United States #West Palm Beach #eNeura #SAVI Dual #Recon Supply

eNeura's SAVI Dual sTMS Neuromodulation Treatment

In a groundbreaking development for migraine treatment, eNeura Inc. has successfully secured a place for its flagship product, the SAVI Dual sTMS Neuromodulation treatment, within Recon Supply's Federal Supply Schedule (FSS) contract. This strategic partnership will significantly improve access to this advanced, non-invasive treatment option for veterans and active-duty military members, alongside other federal healthcare beneficiaries.

What is the SAVI Dual sTMS Treatment?

The SAVI Dual sTMS Neuromodulation treatment is an innovative therapeutic solution, approved by the FDA, designed specifically to address both acute migraines and migraine prevention. Utilizing Transcranial Magnetic Stimulation (TMS), the treatment offers a safe and effective alternative to medications, catering to individuals who have long sought effective relief from the debilitating impacts of migraines.

As the first portable, patient-controlled TMS treatment available, SAVI stands out for its convenience, allowing patients to manage their treatments on their terms. This feature is especially valuable for active military personnel and veterans, many of whom may face unique challenges related to traditional treatment options.

Expanding Access for Those Who Serve

Teresa Kazaros, Chief Operating Officer of eNeura, expressed enthusiasm regarding the inclusion of the SAVI treatment in the FSS contract, stating, "We are thrilled that the SAVI Dual sTMS Neuromodulation treatment is now available through Recon Supply's FSS contract. This partnership reinforces our commitment to ensuring that those who serve our country have access to the most advanced migraine treatment options available."

The impact of this new partnership is significant. The inclusion allows essential federal healthcare agencies, such as the Department of Veterans Affairs (VA), Department of Defense (DOD), and Indian Health Services (IHS), to procure the treatment at pre-negotiated prices. This will enhance accessibility, ensuring that eligible patients receive cutting-edge migraine treatment efficiently.

Steve Clark, CEO of Recon Supply, emphasized the alignment of values between eNeura and Recon Supply, stating, "Adding eNeura's SAVI Dual sTMS Neuromodulation treatment to our FSS contract aligns with our mission to deliver innovative medical technologies to the federal healthcare community. This collaboration enhances access to proven migraine treatments, improving patient care and quality of life."

Addressing the Migraines Epidemic

With millions of Americans grappling with migraines—many of whom are veterans and service members—the expansion of federal access to the SAVI treatment represents a crucial step in addressing this widespread condition. For countless individuals, accessing effective treatments can drastically enhance their quality of life, allowing them to take part in daily activities without the interruption of debilitating migraine pain.

To learn more about eNeura and the SAVI Dual sTMS Neuromodulation treatment, interested parties are encouraged to visit eNeura's official website.

About eNeura Inc.

Founded with the mission to deliver innovative, non-invasive therapies for migraine treatment and prevention, eNeura Inc. continues to set industry standards with its cutting-edge technology. The SAVI treatment is a testament to their commitment to improving patients' lives.

About Recon Supply

Recon Supply, a Service-Disabled Veteran-Owned Small Business (SDVOSB), serves as a reliable distributor of medical technologies. With a focus on delivering exceptional solutions to federal healthcare systems, their involvement in this initiative underscores their dedication to advancing patient care while supporting the veteran community.

This partnership between eNeura and Recon Supply marks a significant milestone in the development and dissemination of effective treatments for one of the most challenging health issues faced by many veterans and military personnel.